Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance

Journal of Virology

Volumn 85, Issue 10, 2011, Pages 5027-5035

  LaMere, Mark W ^a   Moquin, Amy ^b   Eun Hyung Lee, F ^a   Misra, Ravi S ^a   Blair, Patrick J ^c   Haynes, Laura ^b   Randall, Troy D ^a   Lund, Frances E ^a   Kaminski, Denise A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b TRUDEAU INSTITUTE   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; NUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA A (H3N2); INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; STOICHIOMETRY; VIRAL CLEARANCE; VIRUS LOAD; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; DISEASE MODELS, ANIMAL; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; RNA-BINDING PROTEINS; RODENT DISEASES; VACCINATION; VACCINES, SUBUNIT; VIRAL CORE PROTEINS; VIRAL LOAD;

MUS; ORTHOMYXOVIRIDAE; TIPULA IRIDESCENT VIRUS;

EID: 79955426286     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00150-11     Document Type: Article

References (59)

1. Amanna, I. J., N. E. Carlson, and M. K. Slifka. 2007. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357:1903-1915.
2. Bodewes, R., et al. 2010. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J. Gen. Virol. 91:1743-1753.
3. Carragher, D. M., D. A. Kaminski, A. Moquin, L. Hartson, and T. D. Randall. 2008. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 181:4168-4176.
4. Co, M. D., et al. 2009. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 27:319-327.
5. Co, M. D., et al. 2008. Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine 26:1990-1998.
6. Cretescu, L., A. S. Beare, and G. C. Schild. 1978. Formation of antibody to matrix protein in experimental human influenza A virus infections. Infect. Immun. 22:322-327.
7. Du, L., Y. Zhou, and S. Jiang. 2010. Research and development of universal influenza vaccines. Microbes Infect. 12:280-286.
8. Eide, D. M., T. Adnoy, and H. J. Larsen. 1992. Selection for immune response in goats: the effect of immunization procedure on antibody response to diphtheria toxoid and human serum albumin. J. Anim. Sci. 70:1432-1438.
9. Endo, A., et al. 1991. Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haem-agglutinin or nucleoprotein of influenza virus. J. Gen. Virol. 72:699-703.
10. Ennis, F. A., Q. Yi-Hua, and G. C. Schild. 1982. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines. J. Gen. Virol. 58:273-281.
11. Epstein, S. L. 2006. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J. Infect. Dis. 193:49-53.
12. Epstein, S. L., et al. 2005. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23:5404-5410.
13. Epstein, S. L., et al. 1997. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, b2-microglobulin-deficient, and J chain-deficient mice. J. Immunol. 158:1222-1230.
14. Epstein, S. L., et al. 2000. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int. Immunol. 12:91-101.
15. Fecsik, A. I., W. T. Butler, and A. H. Coons. 1964. Studies on antibody production. XI. Variation in the secondary response as a function of the length of the interval between two antigenic stimuli. J. Exp. Med. 120:1041-1049.
16. Fraser, C, et al. 2009. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324:1557-1561.
17. Fu, T. M., et al. 1999. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J. Immunol. 162:4163-4170.
18. Garcia-Canas, V., B. Lorbetskie, D. Bertrand, T. D. Cyr, and M. Girard. 2007. Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection. Anal. Chem. 79:3164-3172.
19. Garcia-Canas, V., B. Lorbetskie, and M. Girard. 2006. Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns. J. Chromatogr. A 1123:225-232.
20. Hammarlund, E., et al. 2003. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9:1131-1137.
21. Hensley, S. E., et al. 2009. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326:734-736.
22. Itoh, Y., et al. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025.
23. Karlsson Hedestam, G. B., et al. 2008. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6:143-155.
24. Koopmans, M., et al. 2004. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363:587-593.
25. Kreijtz, J. H., et al. 2007. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25:612-620.
26. LaMere, M. W., et al. 2011. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186:4331-4339.
27. Liang, S., K. Mozdzanowska, G. Palladino, and W. Gerhard. 1994. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152:1653-1661.
28. Lo, C. Y., et al. 2008. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26:2062-2072.
29. Maines, T. R., et al. 2008. Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol. Rev. 225:68-84.
30. McMichael, A. J., F. M. Gotch, D. W. Dongworth, A. Clark, and C. W. Potter. 1983. Declining T-cell immunity to influenza, 1977-82. Lancet ii:762-764.
31. Mossad, S. B. 2008. 2008-2009 influenza update: a better vaccine match. Cleve. Clin. J. Med. 75:865-870.
32. Mossad, S. B. 2007. Influenza update 2007-2008: vaccine advances, pandemic preparation. Cleve. Clin. J. Med. 74:889-894.
33. Neumann, G., T. Noda, and Y. Kawaoka. 2009. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459:931-939.
34. Nguyen, H. H., et al. 2007. Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire. J. Virol. 81: 9331-9338.
35. Nichol, K. L., J. D. Nordin, D. B. Nelson, J. P. Mullooly, and E. Hak. 2007. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med. 357:1373-1381.
36. Ohmit, S. E., et al. 2006. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 355:2513-2522.
37. Peiris, M., et al. 1999. Human infection with influenza H9N2. Lancet 354: 916-917.
38. Portela, A., and P. Digard. 2002. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J. Gen. Virol. 83:723-734.
39. Powell, T. J., et al. 2007. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J. Immunol. 178:1030-1038.
40. Rangel-Moreno, J., et al. 2008. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J. Immunol. 180:454-463.
41. Sambhara, S., et al. 2001. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell. Immunol. 211:143-153.
42. Scheepers, K., and H. Becht. 1994. Protection of mice against an influenza virus infection by oral vaccination with viral nucleoprotein incorporated into immunostimulating complexes. Med. Microbiol. Immunol. 183:265-278.
43. Shu, L. L., W. J. Bean, and R. G. Webster. 1993. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J. Virol. 67:2723-2729.
44. Smith, G. J. D., et al. 2009. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza epidemic. Nature 459:1122-1125.
45. Sonoguchi, T., H. Naito, M. Hara, Y. Takeuchi, and H. Fukumi. 1985. Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J. Infect. Dis. 151:81-88.
46. Subbarao, K., B. R. Murphy, and A. S. Fauci. 2006. Development of effective vaccines against pandemic influenza. Immunity 24:5-9.
47. Sui, J., et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
48. Sukeno, N., et al. 1979. Anti-nucleoprotein antibody response in influenza A infection. Tohoku J. Exp. Med. 128:241-249.
49. Tamura, S., et al. 1996. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 156:3892-3900.
50. Taubenberger, J. K., and J. C. Kash. 2010. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 7:440-451.
51. Tite, J. P., et al. 1990. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection. Immunology 71:202-207.
52. Tosh, P. K., R. M. Jacobson, and G. A. Poland. 2010. Influenza vaccines: from surveillance through production to protection. Mayo Clin. Proc. 85: 257-273.
53. Tumpey, T. M., M. Renshaw, J. D. Clements, and J. M. Katz. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150.
54. Ulmer, J. B., et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-1749.
55. Ulmer, J. B., et al. 1998. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Virol. 72: 5648-5653.
56. Wei, C. J., et al. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060-1064.
57. Whitley, R. J., and A. S. Monto. 2006. Seasonal and pandemic influenza preparedness: a global threat. J. Infect. Dis. 194(Suppl. 2):S65-S69.
58. Wraith, D. C, A. E. Vessey, and B. A. Askonas. 1987. Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 68:433-440.
59. Yamane, N., T. Odagiri, J. Arikawa, and N. Ishida. 1981. Reversed single-radial-immunodiffusion test: the method for the assay of the antibody to influenza A nucleoprotein. Tohoku J. Exp. Med. 133:245-255.